 Janet Snell-Bergeon
Concepts (504)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 183 | 2025 | 3715 | 17.950 |
Why?
| | Coronary Artery Disease | 44 | 2024 | 698 | 8.580 |
Why?
| | Vascular Calcification | 20 | 2024 | 108 | 7.690 |
Why?
| | Diabetic Nephropathies | 27 | 2025 | 294 | 5.910 |
Why?
| | Diabetic Angiopathies | 29 | 2020 | 259 | 4.970 |
Why?
| | Blood Glucose | 59 | 2025 | 2186 | 4.910 |
Why?
| | Insulin Resistance | 28 | 2024 | 1208 | 4.400 |
Why?
| | Hypoglycemic Agents | 33 | 2025 | 1291 | 4.360 |
Why?
| | Blood Glucose Self-Monitoring | 34 | 2025 | 641 | 3.750 |
Why?
| | Pregnancy in Diabetics | 10 | 2025 | 123 | 3.100 |
Why?
| | Calcinosis | 23 | 2021 | 235 | 2.860 |
Why?
| | Cardiovascular Diseases | 23 | 2025 | 2111 | 2.780 |
Why?
| | Coronary Vessels | 15 | 2023 | 248 | 2.660 |
Why?
| | Adult | 158 | 2025 | 37929 | 2.520 |
Why?
| | Albuminuria | 15 | 2022 | 185 | 2.410 |
Why?
| | Insulin Infusion Systems | 15 | 2025 | 394 | 2.370 |
Why?
| | Obesity | 18 | 2025 | 2992 | 2.320 |
Why?
| | Insulin | 34 | 2025 | 2409 | 2.120 |
Why?
| | Overweight | 4 | 2025 | 558 | 2.090 |
Why?
| | Diabetes Complications | 10 | 2024 | 227 | 2.060 |
Why?
| | Glucagon-Like Peptides | 4 | 2025 | 58 | 1.980 |
Why?
| | Middle Aged | 117 | 2025 | 33479 | 1.900 |
Why?
| | Diabetes Mellitus, Type 2 | 19 | 2024 | 2531 | 1.840 |
Why?
| | Risk Factors | 57 | 2025 | 10388 | 1.820 |
Why?
| | Hypoglycemia | 9 | 2025 | 445 | 1.760 |
Why?
| | Female | 164 | 2025 | 73304 | 1.710 |
Why?
| | Humans | 210 | 2025 | 137585 | 1.660 |
Why?
| | Biomarkers | 26 | 2025 | 4149 | 1.640 |
Why?
| | Male | 146 | 2025 | 67762 | 1.570 |
Why?
| | Uric Acid | 8 | 2018 | 163 | 1.560 |
Why?
| | Glomerular Filtration Rate | 23 | 2025 | 746 | 1.550 |
Why?
| | Atherosclerosis | 9 | 2024 | 415 | 1.430 |
Why?
| | Osteoporotic Fractures | 5 | 2020 | 60 | 1.420 |
Why?
| | Pericardium | 3 | 2024 | 55 | 1.410 |
Why?
| | Diabetic Retinopathy | 5 | 2024 | 189 | 1.380 |
Why?
| | Young Adult | 63 | 2025 | 13209 | 1.350 |
Why?
| | Disease Progression | 34 | 2023 | 2757 | 1.310 |
Why?
| | Calcium | 11 | 2023 | 1199 | 1.300 |
Why?
| | Body Mass Index | 21 | 2025 | 2389 | 1.250 |
Why?
| | Prospective Studies | 29 | 2024 | 7604 | 1.220 |
Why?
| | Longitudinal Studies | 15 | 2024 | 2844 | 1.190 |
Why?
| | Glycopeptides | 3 | 2018 | 43 | 1.180 |
Why?
| | Coronary Disease | 9 | 2015 | 385 | 1.180 |
Why?
| | Adiposity | 7 | 2024 | 518 | 1.130 |
Why?
| | Diet | 4 | 2024 | 1278 | 1.050 |
Why?
| | C-Reactive Protein | 4 | 2024 | 410 | 1.010 |
Why?
| | Fruit | 2 | 2024 | 140 | 1.000 |
Why?
| | Cohort Studies | 32 | 2023 | 5742 | 0.970 |
Why?
| | Diet, Mediterranean | 2 | 2023 | 30 | 0.970 |
Why?
| | Weight Loss | 4 | 2025 | 787 | 0.960 |
Why?
| | Cross-Sectional Studies | 30 | 2024 | 5472 | 0.950 |
Why?
| | Case-Control Studies | 28 | 2025 | 3556 | 0.900 |
Why?
| | Glucagon-Like Peptide 1 | 5 | 2025 | 135 | 0.900 |
Why?
| | Inflammation | 6 | 2024 | 2837 | 0.880 |
Why?
| | Hyperglycemia | 7 | 2022 | 347 | 0.840 |
Why?
| | Cactaceae | 1 | 2023 | 5 | 0.830 |
Why?
| | Vegetables | 1 | 2024 | 157 | 0.810 |
Why?
| | Dietary Fiber | 2 | 2023 | 54 | 0.810 |
Why?
| | Apolipoprotein C-III | 3 | 2023 | 12 | 0.790 |
Why?
| | Trace Elements | 1 | 2022 | 51 | 0.740 |
Why?
| | Follow-Up Studies | 14 | 2023 | 5131 | 0.730 |
Why?
| | Triglycerides | 10 | 2020 | 524 | 0.730 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2019 | 36 | 0.730 |
Why?
| | Prediabetic State | 2 | 2023 | 253 | 0.710 |
Why?
| | Adiponectin | 6 | 2016 | 244 | 0.710 |
Why?
| | Vascular Stiffness | 5 | 2024 | 494 | 0.670 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.650 |
Why?
| | Cystatin C | 8 | 2015 | 65 | 0.650 |
Why?
| | Retrospective Studies | 19 | 2025 | 15657 | 0.630 |
Why?
| | Bone Density | 7 | 2022 | 489 | 0.630 |
Why?
| | Depression | 3 | 2024 | 1397 | 0.610 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 42 | 0.600 |
Why?
| | Uromodulin | 1 | 2018 | 21 | 0.600 |
Why?
| | Apolipoproteins B | 2 | 2015 | 43 | 0.590 |
Why?
| | Cholesterol, HDL | 6 | 2022 | 203 | 0.580 |
Why?
| | Kidney | 7 | 2024 | 1468 | 0.570 |
Why?
| | Islets of Langerhans | 2 | 2022 | 803 | 0.570 |
Why?
| | Cancellous Bone | 1 | 2017 | 23 | 0.560 |
Why?
| | Proteomics | 7 | 2022 | 1111 | 0.560 |
Why?
| | Pilot Projects | 11 | 2024 | 1710 | 0.560 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 354 | 0.550 |
Why?
| | Body Fat Distribution | 1 | 2017 | 49 | 0.540 |
Why?
| | Kidney Function Tests | 3 | 2020 | 160 | 0.530 |
Why?
| | Adolescent | 37 | 2024 | 21513 | 0.530 |
Why?
| | Feeding Behavior | 2 | 2021 | 654 | 0.530 |
Why?
| | Kidney Diseases | 2 | 2012 | 408 | 0.530 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 81 | 0.520 |
Why?
| | Logistic Models | 12 | 2015 | 2074 | 0.510 |
Why?
| | Femur Neck | 4 | 2022 | 61 | 0.510 |
Why?
| | Fear | 1 | 2019 | 338 | 0.510 |
Why?
| | Menopause | 1 | 2019 | 320 | 0.510 |
Why?
| | Prognosis | 9 | 2024 | 4030 | 0.500 |
Why?
| | Tomography, X-Ray Computed | 14 | 2019 | 2691 | 0.480 |
Why?
| | Diabetic Ketoacidosis | 3 | 2024 | 201 | 0.480 |
Why?
| | Self-Management | 3 | 2024 | 176 | 0.480 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2013 | 47 | 0.470 |
Why?
| | Perception | 1 | 2018 | 359 | 0.470 |
Why?
| | Energy Intake | 4 | 2023 | 485 | 0.470 |
Why?
| | Autoimmunity | 3 | 2022 | 908 | 0.470 |
Why?
| | Exercise | 4 | 2023 | 2057 | 0.460 |
Why?
| | Adipose Tissue | 5 | 2024 | 635 | 0.460 |
Why?
| | Pyrazines | 2 | 2013 | 90 | 0.460 |
Why?
| | Dietary Fats | 3 | 2021 | 304 | 0.450 |
Why?
| | Triazoles | 2 | 2013 | 147 | 0.450 |
Why?
| | Brachial Artery | 1 | 2016 | 205 | 0.450 |
Why?
| | Pregnancy Outcome | 5 | 2025 | 416 | 0.450 |
Why?
| | Fractures, Bone | 1 | 2019 | 380 | 0.440 |
Why?
| | Pregnancy | 14 | 2025 | 6763 | 0.440 |
Why?
| | Prevalence | 12 | 2024 | 2734 | 0.440 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2021 | 617 | 0.430 |
Why?
| | Renal Insufficiency | 1 | 2016 | 162 | 0.430 |
Why?
| | Up-Regulation | 2 | 2016 | 843 | 0.430 |
Why?
| | Fibrinogen | 4 | 2023 | 168 | 0.430 |
Why?
| | Sex Factors | 9 | 2024 | 2071 | 0.430 |
Why?
| | Amino Acids, Branched-Chain | 2 | 2024 | 36 | 0.420 |
Why?
| | Self Report | 1 | 2018 | 827 | 0.420 |
Why?
| | Blood Pressure | 10 | 2025 | 1786 | 0.420 |
Why?
| | Metformin | 1 | 2017 | 331 | 0.420 |
Why?
| | Menarche | 2 | 2011 | 60 | 0.420 |
Why?
| | Patient Care Planning | 1 | 2014 | 157 | 0.410 |
Why?
| | Postprandial Period | 2 | 2013 | 107 | 0.400 |
Why?
| | Diglycerides | 3 | 2024 | 61 | 0.400 |
Why?
| | Patient Satisfaction | 2 | 2025 | 660 | 0.400 |
Why?
| | Models, Theoretical | 2 | 2015 | 578 | 0.390 |
Why?
| | Time Factors | 9 | 2024 | 6828 | 0.390 |
Why?
| | Glucagon | 1 | 2013 | 109 | 0.380 |
Why?
| | Muscle, Skeletal | 5 | 2024 | 1724 | 0.380 |
Why?
| | Ketosis | 2 | 2022 | 12 | 0.370 |
Why?
| | Pancreas, Artificial | 2 | 2023 | 84 | 0.370 |
Why?
| | Predictive Value of Tests | 12 | 2020 | 2031 | 0.360 |
Why?
| | Double-Blind Method | 7 | 2025 | 1993 | 0.360 |
Why?
| | Treatment Outcome | 9 | 2025 | 10811 | 0.360 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 740 | 0.350 |
Why?
| | Child | 24 | 2024 | 21935 | 0.350 |
Why?
| | Cholesterol | 6 | 2014 | 410 | 0.350 |
Why?
| | Incidence | 6 | 2021 | 2804 | 0.340 |
Why?
| | Lipids | 5 | 2022 | 672 | 0.340 |
Why?
| | Glucose Clamp Technique | 9 | 2024 | 195 | 0.340 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5778 | 0.340 |
Why?
| | Aged | 20 | 2024 | 23961 | 0.340 |
Why?
| | Age Factors | 11 | 2020 | 3295 | 0.340 |
Why?
| | Lipoproteins, HDL | 3 | 2024 | 77 | 0.320 |
Why?
| | Proteinuria | 2 | 2010 | 97 | 0.320 |
Why?
| | Diabetes Mellitus | 3 | 2024 | 1040 | 0.310 |
Why?
| | Periodontal Diseases | 2 | 2023 | 61 | 0.310 |
Why?
| | Colorado | 9 | 2016 | 4565 | 0.310 |
Why?
| | Risk Assessment | 7 | 2024 | 3457 | 0.310 |
Why?
| | Haptoglobins | 3 | 2015 | 53 | 0.310 |
Why?
| | Cross-Over Studies | 5 | 2024 | 564 | 0.310 |
Why?
| | Creatinine | 9 | 2022 | 499 | 0.300 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.300 |
Why?
| | Aging | 1 | 2019 | 1864 | 0.300 |
Why?
| | Reproductive History | 1 | 2008 | 17 | 0.290 |
Why?
| | Collagen | 1 | 2010 | 452 | 0.280 |
Why?
| | Vitamins | 2 | 2022 | 185 | 0.280 |
Why?
| | United States | 9 | 2024 | 14841 | 0.280 |
Why?
| | Genome-Wide Association Study | 3 | 2019 | 1431 | 0.280 |
Why?
| | Absorptiometry, Photon | 5 | 2022 | 259 | 0.270 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 246 | 0.270 |
Why?
| | Osteoporosis | 3 | 2020 | 243 | 0.270 |
Why?
| | Anthropometry | 3 | 2017 | 213 | 0.270 |
Why?
| | Software | 2 | 2024 | 665 | 0.270 |
Why?
| | Heart Rate | 1 | 2010 | 822 | 0.260 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2019 | 195 | 0.250 |
Why?
| | Contraception | 1 | 2008 | 161 | 0.250 |
Why?
| | Early Diagnosis | 2 | 2017 | 242 | 0.240 |
Why?
| | Sleep | 2 | 2024 | 755 | 0.240 |
Why?
| | Multivariate Analysis | 5 | 2015 | 1509 | 0.230 |
Why?
| | alpha-Macroglobulins | 1 | 2025 | 24 | 0.230 |
Why?
| | Abdominal Wall | 1 | 2004 | 24 | 0.230 |
Why?
| | Hyperinsulinism | 2 | 2024 | 121 | 0.220 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 9 | 0.220 |
Why?
| | Receptors, LDL | 1 | 2024 | 47 | 0.220 |
Why?
| | Apolipoprotein A-I | 1 | 2024 | 30 | 0.220 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 14 | 0.220 |
Why?
| | Insulin, Regular, Human | 1 | 2024 | 43 | 0.220 |
Why?
| | Protective Factors | 1 | 2024 | 93 | 0.210 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 22 | 0.210 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2023 | 86 | 0.210 |
Why?
| | Single-Blind Method | 1 | 2024 | 282 | 0.210 |
Why?
| | Fast Foods | 1 | 2023 | 17 | 0.210 |
Why?
| | Glucose | 3 | 2024 | 1020 | 0.200 |
Why?
| | Calcium, Dietary | 1 | 2023 | 57 | 0.200 |
Why?
| | Food Handling | 1 | 2023 | 61 | 0.200 |
Why?
| | Sweetening Agents | 1 | 2023 | 54 | 0.200 |
Why?
| | Cholesterol, LDL | 3 | 2015 | 365 | 0.200 |
Why?
| | Periodontitis | 1 | 2023 | 53 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 146 | 0.190 |
Why?
| | Polymorphism, Genetic | 5 | 2011 | 660 | 0.190 |
Why?
| | Pulmonary Surfactant-Associated Protein B | 1 | 2022 | 6 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 2 | 2014 | 57 | 0.190 |
Why?
| | Lipoproteins | 2 | 2016 | 168 | 0.190 |
Why?
| | Manganese | 1 | 2022 | 62 | 0.190 |
Why?
| | Quality of Life | 2 | 2025 | 2892 | 0.190 |
Why?
| | Benchmarking | 1 | 2023 | 186 | 0.180 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 151 | 0.180 |
Why?
| | Copper | 1 | 2022 | 104 | 0.180 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.180 |
Why?
| | Mass Spectrometry | 4 | 2017 | 739 | 0.180 |
Why?
| | Inflammasomes | 1 | 2023 | 131 | 0.180 |
Why?
| | Diet Surveys | 1 | 2021 | 95 | 0.180 |
Why?
| | Intra-Abdominal Fat | 3 | 2017 | 91 | 0.180 |
Why?
| | Peptides | 3 | 2017 | 985 | 0.180 |
Why?
| | Beverages | 1 | 2021 | 69 | 0.180 |
Why?
| | Regression Analysis | 7 | 2014 | 1024 | 0.180 |
Why?
| | Insulin, Long-Acting | 1 | 2021 | 63 | 0.180 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2020 | 6 | 0.170 |
Why?
| | Automobile Driving | 1 | 2023 | 148 | 0.170 |
Why?
| | Dyslipidemias | 3 | 2015 | 176 | 0.170 |
Why?
| | Meat | 1 | 2021 | 94 | 0.170 |
Why?
| | Genotype | 7 | 2018 | 1916 | 0.170 |
Why?
| | Blindness | 1 | 2020 | 38 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 852 | 0.170 |
Why?
| | Vitamin D Deficiency | 2 | 2013 | 186 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 956 | 0.160 |
Why?
| | Glomerular Basement Membrane | 1 | 2019 | 8 | 0.160 |
Why?
| | Foam Cells | 1 | 2019 | 18 | 0.160 |
Why?
| | Collagen Type IV | 1 | 2019 | 28 | 0.160 |
Why?
| | Proteome | 2 | 2017 | 472 | 0.160 |
Why?
| | Hip Fractures | 1 | 2020 | 86 | 0.160 |
Why?
| | Bone Development | 1 | 2019 | 54 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2018 | 3284 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2016 | 2828 | 0.150 |
Why?
| | Radius | 1 | 2019 | 39 | 0.150 |
Why?
| | Premenopause | 1 | 2019 | 131 | 0.150 |
Why?
| | Diet Records | 1 | 2019 | 83 | 0.150 |
Why?
| | Waist Circumference | 2 | 2015 | 143 | 0.150 |
Why?
| | Phenotype | 3 | 2024 | 3196 | 0.150 |
Why?
| | Sex Distribution | 3 | 2010 | 375 | 0.150 |
Why?
| | Antioxidants | 1 | 2022 | 584 | 0.150 |
Why?
| | Bone Diseases, Metabolic | 1 | 2019 | 63 | 0.150 |
Why?
| | Weight Gain | 2 | 2019 | 519 | 0.150 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2021 | 177 | 0.140 |
Why?
| | Coronary Angiography | 2 | 2014 | 317 | 0.140 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2018 | 71 | 0.140 |
Why?
| | Linear Models | 4 | 2014 | 849 | 0.140 |
Why?
| | Hospitalization | 2 | 2024 | 2199 | 0.140 |
Why?
| | Tibia | 1 | 2019 | 178 | 0.140 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 48 | 0.140 |
Why?
| | Hyperlipidemias | 2 | 2011 | 120 | 0.140 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 20 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2024 | 654 | 0.140 |
Why?
| | Sphingolipids | 1 | 2018 | 77 | 0.140 |
Why?
| | Accelerometry | 1 | 2018 | 103 | 0.140 |
Why?
| | Sex Characteristics | 4 | 2018 | 762 | 0.130 |
Why?
| | Retinal Vessels | 1 | 2017 | 69 | 0.130 |
Why?
| | Self Care | 2 | 2018 | 380 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 353 | 0.130 |
Why?
| | Depressive Disorder, Major | 1 | 2021 | 364 | 0.130 |
Why?
| | C-Peptide | 1 | 2018 | 163 | 0.130 |
Why?
| | Sleep Deprivation | 1 | 2019 | 174 | 0.130 |
Why?
| | Albumins | 2 | 2016 | 114 | 0.130 |
Why?
| | Autoantigens | 1 | 2019 | 430 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2024 | 986 | 0.130 |
Why?
| | Vascular Capacitance | 1 | 2016 | 4 | 0.130 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 203 | 0.130 |
Why?
| | Dietary Supplements | 2 | 2018 | 561 | 0.130 |
Why?
| | Autoantibodies | 2 | 2022 | 1496 | 0.120 |
Why?
| | Hip Joint | 1 | 2017 | 171 | 0.120 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 14 | 0.120 |
Why?
| | Sitagliptin Phosphate | 2 | 2013 | 33 | 0.120 |
Why?
| | Electrophoresis, Capillary | 2 | 2017 | 20 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6079 | 0.120 |
Why?
| | Hypertension | 5 | 2015 | 1295 | 0.120 |
Why?
| | Pulse Wave Analysis | 3 | 2023 | 272 | 0.120 |
Why?
| | Circadian Rhythm | 1 | 2019 | 468 | 0.110 |
Why?
| | Vitamin E | 1 | 2015 | 124 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 33 | 0.110 |
Why?
| | Fructose | 1 | 2015 | 112 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 117 | 0.110 |
Why?
| | Cannabis | 1 | 2022 | 494 | 0.110 |
Why?
| | Animals | 11 | 2024 | 36940 | 0.110 |
Why?
| | Peptidomimetics | 1 | 2014 | 4 | 0.110 |
Why?
| | Mutation | 3 | 2024 | 3958 | 0.110 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.110 |
Why?
| | Breakfast | 1 | 2014 | 20 | 0.110 |
Why?
| | Liver | 4 | 2015 | 1943 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1113 | 0.100 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 279 | 0.100 |
Why?
| | Goals | 1 | 2015 | 170 | 0.100 |
Why?
| | Risk | 1 | 2016 | 912 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 718 | 0.100 |
Why?
| | HLA-DR2 Antigen | 1 | 2012 | 7 | 0.100 |
Why?
| | Bromocriptine | 2 | 2022 | 30 | 0.100 |
Why?
| | Mice | 9 | 2024 | 17787 | 0.100 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 301 | 0.100 |
Why?
| | Chromatography, Liquid | 2 | 2012 | 433 | 0.100 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.100 |
Why?
| | HLA-DQ beta-Chains | 1 | 2012 | 63 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 281 | 0.100 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 112 | 0.090 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2015 | 455 | 0.090 |
Why?
| | Early Medical Intervention | 1 | 2012 | 57 | 0.090 |
Why?
| | Puberty, Delayed | 1 | 2011 | 9 | 0.090 |
Why?
| | Models, Statistical | 1 | 2015 | 669 | 0.090 |
Why?
| | Menstruation Disturbances | 1 | 2011 | 13 | 0.090 |
Why?
| | Allylamine | 1 | 2011 | 8 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.090 |
Why?
| | Matrix Metalloproteinases | 1 | 2011 | 95 | 0.090 |
Why?
| | Angiopoietin-1 | 1 | 2010 | 11 | 0.090 |
Why?
| | Angiopoietin-2 | 1 | 2010 | 16 | 0.090 |
Why?
| | ROC Curve | 3 | 2020 | 554 | 0.090 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2010 | 79 | 0.090 |
Why?
| | Cardiovascular System | 1 | 2012 | 137 | 0.080 |
Why?
| | Observer Variation | 1 | 2011 | 343 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 209 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2018 | 7635 | 0.080 |
Why?
| | Models, Biological | 3 | 2015 | 1783 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 397 | 0.080 |
Why?
| | Hypolipidemic Agents | 1 | 2010 | 91 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 766 | 0.080 |
Why?
| | Glucose Tolerance Test | 2 | 2024 | 366 | 0.080 |
Why?
| | Rats | 3 | 2015 | 5647 | 0.080 |
Why?
| | Sarcolemma | 2 | 2020 | 43 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 39 | 0.080 |
Why?
| | Age of Onset | 2 | 2009 | 518 | 0.080 |
Why?
| | Anticholesteremic Agents | 1 | 2011 | 153 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.080 |
Why?
| | Puberty | 1 | 2010 | 146 | 0.080 |
Why?
| | Athletes | 2 | 2024 | 423 | 0.070 |
Why?
| | Cytosol | 2 | 2020 | 226 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1091 | 0.070 |
Why?
| | Leptin | 1 | 2010 | 236 | 0.070 |
Why?
| | Alleles | 3 | 2018 | 891 | 0.070 |
Why?
| | Acute Disease | 2 | 2024 | 1007 | 0.070 |
Why?
| | Algorithms | 1 | 2015 | 1704 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Fatty Acids | 1 | 2010 | 443 | 0.070 |
Why?
| | Electrocardiography | 1 | 2010 | 629 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1050 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1946 | 0.070 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.070 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 265 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 490 | 0.070 |
Why?
| | Antidepressive Agents | 1 | 2009 | 236 | 0.070 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 262 | 0.060 |
Why?
| | Mass Screening | 2 | 2013 | 1287 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 85 | 0.060 |
Why?
| | Gene Frequency | 3 | 2018 | 521 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Extracellular Matrix | 1 | 2010 | 528 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 201 | 0.060 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2021 | 159 | 0.060 |
Why?
| | Reference Values | 4 | 2010 | 816 | 0.060 |
Why?
| | Registries | 3 | 2020 | 2035 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2010 | 778 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 66 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 560 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 445 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2024 | 3015 | 0.060 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 57 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 494 | 0.060 |
Why?
| | Apolipoprotein B-100 | 1 | 2024 | 10 | 0.060 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 45 | 0.060 |
Why?
| | Cost Savings | 1 | 2024 | 84 | 0.060 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2024 | 20 | 0.060 |
Why?
| | Labor, Obstetric | 1 | 2024 | 61 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2024 | 78 | 0.050 |
Why?
| | Carnitine | 1 | 2024 | 84 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 82 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1329 | 0.050 |
Why?
| | Drug Approval | 1 | 2024 | 88 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 110 | 0.050 |
Why?
| | Ceramides | 1 | 2024 | 118 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1120 | 0.050 |
Why?
| | Odds Ratio | 3 | 2011 | 1070 | 0.050 |
Why?
| | Mice, Inbred NOD | 2 | 2015 | 601 | 0.050 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 144 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2023 | 90 | 0.050 |
Why?
| | Infant | 2 | 2017 | 9465 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 828 | 0.050 |
Why?
| | Cathepsin D | 1 | 2022 | 18 | 0.050 |
Why?
| | Patient Admission | 1 | 2024 | 197 | 0.050 |
Why?
| | Postpartum Period | 1 | 2025 | 340 | 0.050 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 591 | 0.050 |
Why?
| | Ketone Bodies | 1 | 2021 | 14 | 0.050 |
Why?
| | 3-Hydroxybutyric Acid | 1 | 2021 | 17 | 0.050 |
Why?
| | Smoking | 1 | 2009 | 1627 | 0.050 |
Why?
| | Lipase | 1 | 2002 | 69 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 279 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2526 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 257 | 0.050 |
Why?
| | Glycerol | 2 | 2012 | 94 | 0.050 |
Why?
| | Breath Tests | 1 | 2021 | 87 | 0.040 |
Why?
| | Ketones | 1 | 2021 | 49 | 0.040 |
Why?
| | Technology | 1 | 2021 | 96 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1060 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2023 | 264 | 0.040 |
Why?
| | Diabetes, Gestational | 1 | 2005 | 318 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2020 | 84 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4295 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Phospholipids | 1 | 2021 | 223 | 0.040 |
Why?
| | Body Weight | 1 | 2024 | 985 | 0.040 |
Why?
| | Aryldialkylphosphatase | 1 | 2019 | 18 | 0.040 |
Why?
| | Mitochondria, Muscle | 1 | 2020 | 116 | 0.040 |
Why?
| | Physical Endurance | 1 | 2020 | 275 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 532 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2167 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 50 | 0.040 |
Why?
| | Insulin Aspart | 1 | 2018 | 27 | 0.040 |
Why?
| | Lipocalin-2 | 1 | 2018 | 79 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5757 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.040 |
Why?
| | Injections | 1 | 2018 | 183 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 171 | 0.040 |
Why?
| | Retinal Artery | 1 | 2017 | 17 | 0.040 |
Why?
| | Pelvic Bones | 1 | 2020 | 129 | 0.040 |
Why?
| | Cytokines | 2 | 2017 | 2085 | 0.040 |
Why?
| | Retinal Vein | 1 | 2017 | 13 | 0.040 |
Why?
| | Postmenopause | 1 | 2020 | 366 | 0.040 |
Why?
| | Fundus Oculi | 1 | 2017 | 65 | 0.030 |
Why?
| | Health Behavior | 1 | 2023 | 762 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2002 | 1250 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2020 | 620 | 0.030 |
Why?
| | Canada | 1 | 2018 | 418 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 375 | 0.030 |
Why?
| | Photography | 1 | 2017 | 96 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 165 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2017 | 38 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2018 | 688 | 0.030 |
Why?
| | Blood Banks | 1 | 2016 | 41 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 477 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 474 | 0.030 |
Why?
| | Area Under Curve | 1 | 2017 | 314 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2426 | 0.030 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 152 | 0.030 |
Why?
| | Health Personnel | 1 | 2022 | 710 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1100 | 0.030 |
Why?
| | Autophagy-Related Proteins | 1 | 2015 | 46 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 365 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2015 | 153 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2015 | 116 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2015 | 117 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 385 | 0.030 |
Why?
| | HLA-DQ Antigens | 1 | 2015 | 181 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 157 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1129 | 0.030 |
Why?
| | Purines | 1 | 2015 | 176 | 0.030 |
Why?
| | Vasodilation | 1 | 2017 | 499 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 55 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1325 | 0.030 |
Why?
| | Insulin-Secreting Cells | 1 | 2018 | 377 | 0.030 |
Why?
| | Primary Prevention | 1 | 2015 | 196 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2015 | 302 | 0.030 |
Why?
| | Cause of Death | 1 | 2015 | 434 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 491 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 41 | 0.020 |
Why?
| | Molecular Weight | 1 | 2012 | 335 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 789 | 0.020 |
Why?
| | Colesevelam Hydrochloride | 1 | 2011 | 8 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 948 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 243 | 0.020 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2015 | 2139 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2015 | 718 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 820 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 1272 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2900 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2189 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 431 | 0.020 |
Why?
| | Abdomen | 1 | 2010 | 125 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 18 | 0.020 |
Why?
| | Finland | 1 | 2009 | 85 | 0.020 |
Why?
| | Cysts | 1 | 2010 | 113 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2011 | 266 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 146 | 0.020 |
Why?
| | Proteins | 1 | 2015 | 1009 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | Europe | 1 | 2009 | 414 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 139 | 0.020 |
Why?
| | Spleen | 1 | 2010 | 514 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 94 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2010 | 370 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 514 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2010 | 518 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1316 | 0.020 |
Why?
| | Patient Compliance | 1 | 2011 | 581 | 0.020 |
Why?
| | Body Composition | 1 | 2010 | 684 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 759 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1430 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 696 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2486 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2010 | 788 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 307 | 0.010 |
Why?
| | Maternal Age | 1 | 2005 | 129 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 392 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11074 | 0.010 |
Why?
| | Signal Transduction | 1 | 2015 | 5079 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1317 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1459 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3566 | 0.010 |
Why?
|
|
Snell-Bergeon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|